ArticleNature nanotechnology2018
Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease.
Open access · greenAbstract read
In one paragraph
Article in Nature nanotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
31.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 447 citations in OpenAlex.
- Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Nanotechnology in neurosurgery: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Pooled it
- Graphene Quantum Dots in Neurodegeneration: Protein Aggregation and the Microglial State as Therapeutic Targets.Nanomaterials (Basel, Switzerland) · 2026Review
- The Complex Interplay in Quantum Dot Neurotoxicity: From Environmental Exposure to Disruption of Neural Homeostasis.Toxics · 2026Review
- Nanoparticles in Vascular Dementia: Advantages and Challenges.CNS neuroscience & therapeutics · 2026Review
- Graphene Quantum Dots Mitigate Oxidative Stress in Bacteria.bioRxiv : the preprint server for biology · 2026Article
- Nitrogen-Doped Graphene Quantum Dots Conjugated to Leucettinib-21 Rescue Differentiating Zebrafish Purkinje Cells by Inhibiting Dyrk1A Kinase.ACS applied nano materials · 2026Article
- Photonic and nanomaterial-driven optical biosensing strategies for Parkinson's disease.Mikrochimica acta · 2026Review
- Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson's disease.Drug delivery and translational research · 2026Article
- Nanotechnology in Parkinson's Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes.Drug delivery and translational research · 2026Review
- From biomolecular condensates to functional nanomaterials: LLPS-inspired frameworks for nanoscale hydrogels and adaptive materials.Journal of nanobiotechnology · 2026Review
- High-affinity nitrogen-doped graphene quantum dots for selectiveRSC advances · 2026Article
- Therapeutic and Diagnostic Implications of Carbon Dot: An Advancement in the Avenue towards Cancer, Diabetes and Neurodegenerative Disorders.Pharmaceutical nanotechnology · 2026Review
- Characterization and evaluation of the ability of graphene quantum dots to affect α-synuclein aggregation in synucleinopathy models.Science and technology of advanced materials · 2026Article
- Polyhalogenated Carbazole Impairs Dopaminergic Neurons through Dysregulation of Liquid-Liquid Phase Separation in Caenorhabditis elegans.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Therapeutic Potential of Graphene Quantum Dots on Pterygium Cells.Investigative ophthalmology & visual science · 2025Article
- N-Amino Peptide-Graphene Quantum Dot Loaded Small Extracellular Vesicles for Targeted Therapy of Tauopathies.Advanced nanobiomed research · 2025Article
- Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead.AAPS PharmSciTech · 2025Review
- Incidental vs. Engineered Nanoparticles in Alzheimer's and Parkinson's Disease: Pathological Pathways and Therapeutic Interventions.Nano research · 2025Article
- Neurochemical Characterization of A53T-Alpha-Synuclein and 6-Hydroxydopamine Rat Models for Parkinson's Disease through Animal PET Imaging Analysis.Journal of Korean Neurosurgical Society · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 3 institutions in 5 countries.
Donghoon KimNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Je Min YooDepartment of Chemistry, College of Natural Science, Seoul National University, Seoul, Republic of Korea.
Heehong HwangNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Junghee LeeInter-University Semiconductor Research Centre, Seoul National University, Seoul, Republic of Korea.
Su Hyun LeeNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Seung Pil YunNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Myung Jin ParkDepartment of Chemistry, College of Natural Science, Seoul National University, Seoul, Republic of Korea.
MinJun LeeDepartment of Chemistry, College of Natural Science, Seoul National University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-4011-3048
Seulah ChoiNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sang Ho KwonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Saebom LeeNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Seung-Hwan KwonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5862-1630
Sangjune KimNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yong Joo ParkThe Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Misaki KinoshitaInstitute for Protein Research, Osaka University, Yamadaoka, Osaka, Japan.
Young-Ho LeeInstitute for Protein Research, Osaka University, Yamadaoka, Osaka, Japan.
Seokmin ShinDepartment of Chemistry, College of Natural Science, Seoul National University, Seoul, Republic of Korea.
Seung R PaikSchool of Chemical and Biological Engineering, College of Engineering, Seoul National University, Seoul, Republic of Korea.
Sung Joong LeeDepartment of Neuroscience and Physiology, Interdisciplinary Program in Neuroscience, Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Seulki LeeThe Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Byung Hee HongDepartment of Chemistry, College of Natural Science, Seoul National University, Seoul, Republic of Korea. byunghee@snu.ac.kr.
Han Seok KoNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. hko3@jhmi.edu.
Seoul National University · KRJohns Hopkins University · USProtein Research Foundation · JP
Funding
Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 1998 to 2019
$38.8MGlucocerebrosidase Biology and It's Role in Parkinson's DiseaseR01NS082205 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 2013 to 2017
$1.8MCharacterization and Validation of Mouse VPS35 Model of Parkinson's DiseaseR21NS098006 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 2017 to 2018
$449kNINDS NIH HHS P50 NS038377NINDS NIH HHS R01 NS082205NINDS NIH HHS R21 NS098006
Abstract
Though emerging evidence indicates that the pathogenesis of Parkinson's disease is strongly correlated to the accumulation
Indexed as
GraphiteQuantum Dotsalpha-SynucleinAnimalsBlood-Brain BarrierCells, CulturedHumansLewy BodiesMiceParkinson DiseaseProtein Aggregation, PathologicalSynapsesalpha-SynucleinGraphiteSnca protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.